blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2914586

EP2914586 - BRUTON'S TYROSINE KINASE INHIBITORS [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  09.02.2018
Database last updated on 20.09.2024
FormerThe patent has been granted
Status updated on  03.03.2017
FormerGrant of patent is intended
Status updated on  23.11.2016
FormerRequest for examination was made
Status updated on  11.11.2016
Most recent event   Tooltip17.07.2020Lapse of the patent in a contracting state
New state(s): AL		published on 19.08.2020  [2020/34]
Applicant(s)For all designated states
Pfizer Inc.
235 East 42nd Street
New York, NY 10017 / US
[2015/37]
Inventor(s)01 / SPRINGER, John Robert
203 Willow Park Drive
Wentzville, Missouri 63385 / US
02 / DEVADAS, Balekudru
2175 Parasol Drive
Chesterfield, Missouri 63017 / US
03 / GARLAND, Danny James
5522 Lamprecht Lane
House Springs, Missouri 06351 / US
04 / GRAPPERHAUS, Margaret Lanahan
503 Trout Lane
Troy, Illinois 62294 / US
05 / HAN, Seungil
286 Deerfield Ridge Drive
Mystic, Connecticut 06355 / US
06 / HOCKERMAN, Susan Landis
636 Pearl Avenue
Kirkwood, Missouri 63122 / US
07 / HUGHES, Robert Owen
8 Shadow Ridge Circle
Newtown, Connecticut 06470 / US
08 / SAIAH, Eddine
12 Stedman Street, No. 2
Brookline, Massachusetts 02446 / US
09 / SCHNUTE, Mark Edward
10 Chase Path
Acton, Massachusetts 01720 / US
10 / SELNESS, Shaun Raj
1875 Cedarmill Drive
Chesterfield, Missouri 63017 / US
11 / WALKER, Daniel Patrick
124 Murdoch Court
Augusta, Missouri 63332 / US
12 / WAN, Zhao-Kui
30 Sanderson Road
Lexington, Massachusetts 02420 / US
13 / XING, Li
8 Great Rock Road
Lexington, Massachusetts 02421 / US
14 / ZAPF, Christoph Wolfgang
48 Kinder Circle
Marlborough, Massachusetts 01752 / US
15 / SCHMIDT, Michelle, Ann
5764 Lake Briar Drive
Millstadt, Illinois 62260 / US
 [2017/14]
Former [2015/37]01 / SPRINGER, John Robert
203 Willow Park Drive
Wentzville, Missouri 63385 / US
02 / DEVADAS, Balekudru
2175 Parasol Drive
Chesterfield, Missouri 63017 / US
03 / GARLAND, Danny James
5522 Lamprecht Lane
House Springs, Missouri 06351 / US
04 / GRAPPERHAUS, Margaret Lanahan
503 Trout Lane
Troy, Illinois 62294 / US
05 / HAN, Seungil
286 Deerfield Ridge Drive
Mystic, Connecticut 06355 / US
06 / HOCKERMAN, Susan Landis
636 Pearl Avenue
Kirkwood, Missouri 63122 / US
07 / HUGHES, Robert Owen
8 Shadow Ridge Circle
Newtown, Connecticut 06470 / US
08 / SAIAH, Eddine
12 Stedman Street 2
Brookline, Massachusetts 02446 / US
09 / SCHNUTE, Mark Edward
10 Chase Path
Acton, Massachusetts 01720 / US
10 / SELNESS, Shaun Raj
1875 Cedarmill Drive
Chesterfield, Missouri 63017 / US
11 / WALKER, Daniel Patrick
124 Murdoch Court
Augusta, Missouri 63332 / US
12 / WAN, Zhao-Kui
30 Sanderson Road
Lexington, Massachusetts 02420 / US
13 / XING, Li
8 Great Rock Road
Lexington, Massachusetts 02421 / US
14 / ZAPF, Christoph Wolfgang
48 Kinder Circle
Marlborough, Massachusetts 01752 / US
15 / SCHMIDT, Michelle, Ann
5764 Lake Briar Drive
Millstadt, Illinois 62260 / US
Representative(s)Pfizer
European Patent Department
23-25 avenue du Docteur Lannelongue
75668 Paris Cedex 14 / FR
[2015/37]
Application number, filing date13792494.001.11.2013
[2015/37]
WO2013IB59846
Priority number, dateUS201261721920P02.11.2012         Original published format: US 201261721920 P
US201361772028P04.03.2013         Original published format: US 201361772028 P
[2015/37]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2014068527
Date:08.05.2014
Language:EN
[2014/19]
Type: A1 Application with search report 
No.:EP2914586
Date:09.09.2015
Language:EN
The application published by WIPO in one of the EPO official languages on 08.05.2014 takes the place of the publication of the European patent application.
[2015/37]
Type: B1 Patent specification 
No.:EP2914586
Date:05.04.2017
Language:EN
[2017/14]
Search report(s)International search report - published on:EP08.05.2014
ClassificationIPC:C07D401/04, A61K31/4155, A61K31/454, A61P29/00, A61P35/00
[2015/37]
CPC:
C07D401/04 (EP,CN,US); A61P29/00 (EP); A61P35/00 (EP,US);
A61P35/02 (EP,US); A61P37/00 (EP,US); A61P37/02 (EP,US);
A61P37/06 (EP); A61P43/00 (EP); C07D401/14 (CN) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2015/37]
Extension statesBA02.06.2015
ME02.06.2015
TitleGerman:HEMMER DER BRUTON-TYROSINKINASE[2015/37]
English:BRUTON'S TYROSINE KINASE INHIBITORS[2015/37]
French:INHIBITEURS DE LA TYROSINE KINASE DE BRUTON[2015/37]
Entry into regional phase02.06.2015National basic fee paid 
02.06.2015Designation fee(s) paid 
02.06.2015Examination fee paid 
Examination procedure30.04.2015Amendment by applicant (claims and/or description)
02.06.2015Examination requested  [2015/37]
14.07.2016Communication of intention to grant the patent
09.11.2016Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
24.11.2016Communication of intention to grant the patent
22.02.2017Fee for grant paid
22.02.2017Fee for publishing/printing paid
22.02.2017Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  14.07.2016
Opposition(s)08.01.2018No opposition filed within time limit [2018/11]
Fees paidRenewal fee
30.11.2015Renewal fee patent year 03
30.11.2016Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU01.11.2013
AL05.04.2017
AT05.04.2017
CY05.04.2017
CZ05.04.2017
DK05.04.2017
EE05.04.2017
FI05.04.2017
HR05.04.2017
LT05.04.2017
LV05.04.2017
MC05.04.2017
MK05.04.2017
NL05.04.2017
PL05.04.2017
PT05.04.2017
RO05.04.2017
RS05.04.2017
SE05.04.2017
SI05.04.2017
SK05.04.2017
SM05.04.2017
TR05.04.2017
BG05.07.2017
NO05.07.2017
GR06.07.2017
IS05.08.2017
LU01.11.2017
MT01.11.2017
BE30.11.2017
CH30.11.2017
LI30.11.2017
[2020/34]
Former [2020/28]HU01.11.2013
AT05.04.2017
CY05.04.2017
CZ05.04.2017
DK05.04.2017
EE05.04.2017
FI05.04.2017
HR05.04.2017
LT05.04.2017
LV05.04.2017
MC05.04.2017
MK05.04.2017
NL05.04.2017
PL05.04.2017
PT05.04.2017
RO05.04.2017
RS05.04.2017
SE05.04.2017
SI05.04.2017
SK05.04.2017
SM05.04.2017
TR05.04.2017
BG05.07.2017
NO05.07.2017
GR06.07.2017
IS05.08.2017
LU01.11.2017
MT01.11.2017
BE30.11.2017
CH30.11.2017
LI30.11.2017
Former [2020/15]HU01.11.2013
AT05.04.2017
CY05.04.2017
CZ05.04.2017
DK05.04.2017
EE05.04.2017
FI05.04.2017
HR05.04.2017
LT05.04.2017
LV05.04.2017
MC05.04.2017
MK05.04.2017
NL05.04.2017
PL05.04.2017
RO05.04.2017
RS05.04.2017
SE05.04.2017
SI05.04.2017
SK05.04.2017
SM05.04.2017
TR05.04.2017
BG05.07.2017
NO05.07.2017
GR06.07.2017
IS05.08.2017
LU01.11.2017
MT01.11.2017
BE30.11.2017
CH30.11.2017
LI30.11.2017
Former [2019/51]HU01.11.2013
AT05.04.2017
CY05.04.2017
CZ05.04.2017
DK05.04.2017
EE05.04.2017
FI05.04.2017
HR05.04.2017
LT05.04.2017
LV05.04.2017
MC05.04.2017
MK05.04.2017
NL05.04.2017
PL05.04.2017
RO05.04.2017
RS05.04.2017
SE05.04.2017
SI05.04.2017
SK05.04.2017
SM05.04.2017
BG05.07.2017
NO05.07.2017
GR06.07.2017
IS05.08.2017
LU01.11.2017
MT01.11.2017
BE30.11.2017
CH30.11.2017
LI30.11.2017
Former [2019/47]HU01.11.2013
AT05.04.2017
CY05.04.2017
CZ05.04.2017
DK05.04.2017
EE05.04.2017
FI05.04.2017
HR05.04.2017
LT05.04.2017
LV05.04.2017
MC05.04.2017
NL05.04.2017
PL05.04.2017
RO05.04.2017
RS05.04.2017
SE05.04.2017
SI05.04.2017
SK05.04.2017
SM05.04.2017
BG05.07.2017
NO05.07.2017
GR06.07.2017
IS05.08.2017
LU01.11.2017
MT01.11.2017
BE30.11.2017
CH30.11.2017
LI30.11.2017
Former [2019/31]HU01.11.2013
AT05.04.2017
CZ05.04.2017
DK05.04.2017
EE05.04.2017
FI05.04.2017
HR05.04.2017
LT05.04.2017
LV05.04.2017
MC05.04.2017
NL05.04.2017
PL05.04.2017
RO05.04.2017
RS05.04.2017
SE05.04.2017
SI05.04.2017
SK05.04.2017
SM05.04.2017
BG05.07.2017
NO05.07.2017
GR06.07.2017
IS05.08.2017
LU01.11.2017
MT01.11.2017
BE30.11.2017
CH30.11.2017
LI30.11.2017
Former [2018/50]AT05.04.2017
CZ05.04.2017
DK05.04.2017
EE05.04.2017
FI05.04.2017
HR05.04.2017
LT05.04.2017
LV05.04.2017
MC05.04.2017
NL05.04.2017
PL05.04.2017
RO05.04.2017
RS05.04.2017
SE05.04.2017
SI05.04.2017
SK05.04.2017
SM05.04.2017
BG05.07.2017
NO05.07.2017
GR06.07.2017
IS05.08.2017
LU01.11.2017
MT01.11.2017
BE30.11.2017
CH30.11.2017
LI30.11.2017
Former [2018/43]AT05.04.2017
CZ05.04.2017
DK05.04.2017
EE05.04.2017
FI05.04.2017
HR05.04.2017
LT05.04.2017
LV05.04.2017
MC05.04.2017
NL05.04.2017
PL05.04.2017
RO05.04.2017
RS05.04.2017
SE05.04.2017
SI05.04.2017
SK05.04.2017
SM05.04.2017
BG05.07.2017
NO05.07.2017
GR06.07.2017
IS05.08.2017
LU01.11.2017
MT01.11.2017
CH30.11.2017
LI30.11.2017
Former [2018/41]AT05.04.2017
CZ05.04.2017
DK05.04.2017
EE05.04.2017
FI05.04.2017
HR05.04.2017
LT05.04.2017
LV05.04.2017
MC05.04.2017
NL05.04.2017
PL05.04.2017
RO05.04.2017
RS05.04.2017
SE05.04.2017
SI05.04.2017
SK05.04.2017
SM05.04.2017
BG05.07.2017
NO05.07.2017
GR06.07.2017
IS05.08.2017
LU01.11.2017
CH30.11.2017
LI30.11.2017
Former [2018/33]AT05.04.2017
CZ05.04.2017
DK05.04.2017
EE05.04.2017
FI05.04.2017
HR05.04.2017
LT05.04.2017
LV05.04.2017
MC05.04.2017
NL05.04.2017
PL05.04.2017
RO05.04.2017
RS05.04.2017
SE05.04.2017
SI05.04.2017
SK05.04.2017
SM05.04.2017
BG05.07.2017
NO05.07.2017
GR06.07.2017
IS05.08.2017
CH30.11.2017
LI30.11.2017
Former [2018/25]AT05.04.2017
CZ05.04.2017
DK05.04.2017
EE05.04.2017
FI05.04.2017
HR05.04.2017
LT05.04.2017
LV05.04.2017
NL05.04.2017
PL05.04.2017
RO05.04.2017
RS05.04.2017
SE05.04.2017
SI05.04.2017
SK05.04.2017
SM05.04.2017
BG05.07.2017
NO05.07.2017
GR06.07.2017
IS05.08.2017
Former [2018/11]AT05.04.2017
CZ05.04.2017
DK05.04.2017
EE05.04.2017
FI05.04.2017
HR05.04.2017
LT05.04.2017
LV05.04.2017
NL05.04.2017
PL05.04.2017
RO05.04.2017
RS05.04.2017
SE05.04.2017
SK05.04.2017
SM05.04.2017
BG05.07.2017
NO05.07.2017
GR06.07.2017
IS05.08.2017
Former [2018/10]AT05.04.2017
CZ05.04.2017
DK05.04.2017
EE05.04.2017
FI05.04.2017
HR05.04.2017
LT05.04.2017
LV05.04.2017
NL05.04.2017
PL05.04.2017
RO05.04.2017
RS05.04.2017
SE05.04.2017
SK05.04.2017
BG05.07.2017
NO05.07.2017
GR06.07.2017
IS05.08.2017
Former [2018/09]AT05.04.2017
DK05.04.2017
EE05.04.2017
FI05.04.2017
HR05.04.2017
LT05.04.2017
LV05.04.2017
NL05.04.2017
PL05.04.2017
RS05.04.2017
SE05.04.2017
BG05.07.2017
NO05.07.2017
GR06.07.2017
IS05.08.2017
Former [2017/50]AT05.04.2017
FI05.04.2017
HR05.04.2017
LT05.04.2017
LV05.04.2017
NL05.04.2017
PL05.04.2017
RS05.04.2017
SE05.04.2017
BG05.07.2017
NO05.07.2017
GR06.07.2017
IS05.08.2017
Former [2017/49]AT05.04.2017
FI05.04.2017
HR05.04.2017
LT05.04.2017
NL05.04.2017
NO05.07.2017
GR06.07.2017
IS05.08.2017
Former [2017/48]NL05.04.2017
Cited inInternational search[A]WO2009011880  (AMGEN INC [US], et al) [A] 1-28 * page 1, paragraph [0003] * * claims 1,8 *;
 [A]WO2011029046  (BIOGEN IDEC INC [US], et al) [A] 1-28 * page 1, paragraph [0002] * * claim 1 *;
 [A]WO2011159857  (BRISTOL MYERS SQUIBB CO [US], et al) [A] 1-28 * page 1, paragraph [0002] ** claim 1 *
by applicantUS5033252
 US5052558
 US5323907
 US6326469
 US2012252822
    - D.M. WEIR & C.C. BLACKWELL,, Handbook of experimental immunology, UNKNOWN
    - NOGRADY, Medicinal Chemistry A Biochemical Approach, OXFORD UNIVERSITY PRESS, (1985), pages 388 - 392
    - SILVERMAN, The Organic Chemistry of Drug Design and Drug Action, ACADEMIC PRESS, INC., (1992), pages 352 - 401
    - SAULNIER ET AL., BIOORGANIC AND MEDICINAL CHEMISTRY LETTERS, (1994), vol. 4, page 1985
    - FEDORAK ET AL., AM. J. PHYSIOL., (1995), vol. 269, pages G210 - 218
    - MCLOED ET AL., GASTROENTEROL, (1994), vol. 106, pages 405 - 413
    - HOCHHAUS ET AL., BIOMED. CHROM., (1992), vol. 6, pages 283 - 286
    - J. LARSEN; H. BUNDGAARD, INT. J. PHARMACEUTICS, (1987), vol. 37, page 87
    - J. LARSEN ET AL., INT. J. PHARMACEUTICS, (1988), vol. 47, page 103
    - SINKULA ET AL., J. PHARM. SCI., (1975), vol. 64, pages 181 - 210
    - T. HIGUCHI; V. STELLA, Pro-drugs as Novel Delivery Systems, A.C.S. SYMPOSIUM SERIES, vol. 14
    - NANDAKUMAR ET AL., AM. J. PATHOL, (2003), vol. 163, pages 1827 - 1837
    - PAGEL ET AL., CLIN CANCER RES, (2005), vol. 11, no. 13, pages 4857 - 4866
    - NISITANI ET AL., PROC. NATL. ACAD. SCI, USA, (1999), vol. 96, pages 2221 - 2226
    - J. ORG. CHEM., (1981), vol. 46, pages 940 - 948
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.